Real-time Estimate
Cboe BZX
15:42:09 29/04/2024 BST
|
5-day change
|
1st Jan Change
|
5.35
USD
|
+1.90%
|
|
+4.26%
|
-32.46%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,188
|
1,199
|
1,678
|
763.3
|
671.4
|
506
|
-
|
-
|
Enterprise Value (EV)
1 |
834.5
|
785.6
|
943.1
|
50.48
|
122.5
|
-42.91
|
-197
|
506
|
P/E ratio
|
-10.1
x
|
-6.18
x
|
-45.9
x
|
-5.7
x
|
-5.12
x
|
-2.45
x
|
-3.4
x
|
-4.23
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
56
x
|
56.8
x
|
8.1
x
|
5.71
x
|
6.92
x
|
8.12
x
|
4.35
x
|
2.43
x
|
EV / Revenue
|
39.3
x
|
37.2
x
|
4.55
x
|
0.38
x
|
1.26
x
|
-0.69
x
|
-1.69
x
|
2.43
x
|
EV / EBITDA
|
-7.54
x
|
-4.15
x
|
-30.4
x
|
-0.38
x
|
-0.84
x
|
0.21
x
|
1.31
x
|
-5.15
x
|
EV / FCF
|
-7.28
x
|
-
|
3.19
x
|
-2.07
x
|
-0.66
x
|
0.28
x
|
1.56
x
|
-2.71
x
|
FCF Yield
|
-13.7%
|
-
|
31.3%
|
-48.4%
|
-152%
|
360%
|
64%
|
-36.9%
|
Price to Book
|
6.11
x
|
4.49
x
|
5.63
x
|
3.57
x
|
4.98
x
|
4.73
x
|
4.82
x
|
-
|
Nbr of stocks (in thousands)
|
68,924
|
79,243
|
81,276
|
82,702
|
84,136
|
96,385
|
-
|
-
|
Reference price
2 |
17.23
|
15.13
|
20.65
|
9.230
|
7.980
|
5.250
|
5.250
|
5.250
|
Announcement Date
|
24/03/20
|
25/02/21
|
24/02/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
21.22
|
21.1
|
207.1
|
133.6
|
97.06
|
62.31
|
116.2
|
208
|
EBITDA
1 |
-110.6
|
-189.3
|
-31.03
|
-132.1
|
-146
|
-199.7
|
-149.9
|
-98.25
|
EBIT
1 |
-114.4
|
-195.2
|
-37.36
|
-137.8
|
-151.7
|
-226.6
|
-170.9
|
-132.6
|
Operating Margin
|
-539.16%
|
-925.08%
|
-18.04%
|
-103.16%
|
-156.33%
|
-363.68%
|
-147%
|
-63.77%
|
Earnings before Tax (EBT)
1 |
-105.4
|
-190.2
|
-36.33
|
-130.1
|
-125.2
|
-199.9
|
-127.3
|
-143.4
|
Net income
1 |
-105.4
|
-190.2
|
-36.33
|
-133.3
|
-130.4
|
-200.9
|
-129
|
-143.4
|
Net margin
|
-496.65%
|
-901.64%
|
-17.54%
|
-99.77%
|
-134.34%
|
-322.37%
|
-110.94%
|
-68.94%
|
EPS
2 |
-1.710
|
-2.450
|
-0.4500
|
-1.620
|
-1.560
|
-2.141
|
-1.544
|
-1.240
|
Free Cash Flow
1 |
-114.6
|
-
|
295.3
|
-24.45
|
-186.5
|
-154.4
|
-126
|
-186.7
|
FCF margin
|
-539.95%
|
-
|
142.6%
|
-18.3%
|
-192.19%
|
-247.74%
|
-108.42%
|
-89.79%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/03/20
|
25/02/21
|
24/02/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
182.4
|
13.99
|
24.47
|
79.85
|
14.85
|
14.44
|
16.55
|
56.21
|
9.109
|
15.19
|
15.76
|
15.76
|
15.76
|
15.76
|
250
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-46.02
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
126.3
|
-55.73
|
-44.12
|
9.475
|
-47.75
|
-55.44
|
-50.12
|
-3.589
|
-50.58
|
-47.45
|
-52.08
|
-55
|
-57.88
|
-56.78
|
191.2
|
Operating Margin
|
69.25%
|
-398.23%
|
-180.29%
|
11.87%
|
-321.49%
|
-383.92%
|
-302.83%
|
-6.38%
|
-555.31%
|
-312.4%
|
-330.46%
|
-349.01%
|
-367.23%
|
-360.29%
|
76.46%
|
Earnings before Tax (EBT)
1 |
126.6
|
-55.61
|
-43.86
|
10.92
|
-45.42
|
-51.71
|
-44.96
|
2.768
|
-43.22
|
-39.77
|
-47.16
|
-50.38
|
-53.54
|
-48.86
|
196.7
|
Net income
1 |
126.6
|
-55.61
|
-44.62
|
9.883
|
-46.15
|
-52.43
|
-45.86
|
1.375
|
-44.48
|
-41.43
|
-50.14
|
-53.51
|
-51.83
|
-49.24
|
188.5
|
Net margin
|
69.4%
|
-397.37%
|
-182.3%
|
12.38%
|
-310.72%
|
-363.07%
|
-277.1%
|
2.45%
|
-488.25%
|
-272.77%
|
-318.16%
|
-339.5%
|
-328.88%
|
-312.45%
|
75.39%
|
EPS
2 |
1.490
|
-0.6800
|
-0.5400
|
0.1200
|
-0.5600
|
-0.6300
|
-0.5500
|
0.0200
|
-0.5300
|
-0.4900
|
-0.5357
|
-0.5529
|
-0.5371
|
-0.5143
|
1.930
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/11/21
|
24/02/22
|
05/05/22
|
04/08/22
|
08/11/22
|
28/02/23
|
04/05/23
|
03/08/23
|
07/11/23
|
27/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
353
|
413
|
735
|
713
|
549
|
549
|
703
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-115
|
-
|
295
|
-24.4
|
-187
|
-154
|
-126
|
-187
|
ROE (net income / shareholders' equity)
|
-217%
|
-82.3%
|
-12.8%
|
-51.8%
|
-74.8%
|
-172%
|
-132%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-18.5%
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
704.7
|
-
|
-
|
-
|
Book Value Per Share
2 |
2.820
|
3.370
|
3.670
|
2.590
|
1.600
|
1.110
|
1.090
|
-
|
Cash Flow per Share
2 |
-
|
-2.140
|
3.710
|
-0.2500
|
-2.200
|
-1.710
|
-1.850
|
-
|
Capex
1 |
15.3
|
5.03
|
3.25
|
4.12
|
2.38
|
6.62
|
8.17
|
8.52
|
Capex / Sales
|
71.94%
|
23.85%
|
1.57%
|
3.08%
|
2.45%
|
10.62%
|
7.03%
|
4.1%
|
Announcement Date
|
24/03/20
|
25/02/21
|
24/02/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
5.25
USD Average target price
16.22
USD Spread / Average Target +208.99% Consensus |
1st Jan change
|
Capi.
|
---|
| -32.46% | 506M | | -2.19% | 103B | | +1.41% | 95.28B | | +2.59% | 22.15B | | -15.87% | 21.02B | | -8.35% | 18.15B | | -41.01% | 16.73B | | -13.89% | 16.05B | | +3.95% | 13.68B | | +34.71% | 12.17B |
Bio Therapeutic Drugs
|